α-Helical CRF (9-41) trifluoroacetate salt

α-Helical Corticotropin Releasing Factor (9-41) is a corticotropin releasing factor (CRF) antagonist. α-Helical Corticotropin Releasing Factor (9-41) decreases plasma growth hormone (GH) values in vivo[1][2].

Signaling Pathways >> GPCR/G Protein >> CRFR

Research Areas >> Inflammation/Immunology

α-Helical Corticotropin Releasing Factor (9-41) (10 μg; the third or lateral ventricle of the brain injection; once) significantly decreases plasma GH values[1]. α-Helical Corticotropin Releasing Factor (9-41) (100 ng/kg; i.c.v. once) affects rhlL-1/β-induced enhancement of the splenic sympathetic activity[2]. Animal Model: Adult Sprague-Dawley rats[1] Dosage: 10 μg Administration: The third or lateral ventricle of the brain injection; 10 μg once Result: Abolished the 10 min electroshocks-produced the decreasing of plasma GH levels by injected into the third or lateral ventricle of the brain 45 min before exposure to stress. Animal Model: Adult Sprague-Dawley rats with immunity of endogenous somatostatin (SS)[1] Dosage: 10 μg Administration: Lateral ventricle brain injection; 10 μg once Result: Showed no effect on plasma GH values in rats whose endogenous SS had been immunoneutralized, but did interfere with the stimulatory effect of GH-releasing factor (GRF). Animal Model: Male Wistar rats with rhlL-1/β injection[2] Dosage: 100 ng/kg Administration: Intracerebroventricularly injection; 100 ng/kg once Result: Completely blocked the rhlL-1/β-induced enhancement of the splenic sympathetic activity, but failed to alter the enhancement of nociceptive behaviors caused by rhlL-1/β.

[1]. Rivier C, Vale W. Involvement of corticotropin-releasing factor and somatostatin in stress-induced inhibition of growth hormone secretion in the rat. Endocrinology. 1985 Dec;117(6):2478-82.

[2]. Takakazu Oka, et al. Intracerebroventricular injection of interleukin-1/β induces hyperalgesia in rats. Brain Research, 624 (1993) 61-68.